BTTX's Business Model
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.bettertx.com |
CEO (Chief Executive Officer) | David P. Perry |
Number of Employees | |
IPO date | March 17, 2021 |
BTTX Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 548 Market Street |
City | San Francisco |
State | CA |
Phone | 415 887 2311 |
Zip Code | 94104 |
Other Identifiers | |
CIK | 0001832415 |
ISIN | US08773T1043 |
CUSIP | 08773T104 |
Open | 0.0001 |
Previous Close | 0.0001 |
Volume | 172 |
Average Volume | 11.61 Thou. |
Day’s Range | 0.0001 – 0.0001 |
52 Week Range | 0.0001-0.016 |
MA (50) | 0.000126 |
MA (200) | 0.0001615 |
Market Cap | 5.45 Thou. |
Shares Out. | 54.52 Mil. |
Earnings Date | Jul 21, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |